• About us
• Contact

Advertisement

Organisation › Details

Nkarta Inc. (Nkarta Therapeutics) (NKTX)

Nkarta, Inc. focuses on combining its natural killer (NK) cell expansion and cryopreservation platform with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. Nkarta’s mission is to discover, develop and deliver novel off-the-shelf NK cell therapy product candidates that have a profound impact on patients. *

 

	Start	2015-01-01 established
	Industry	cell therapy
	Industry 2	NK cell therapy (natural killer cell therapy)
	Person	Hastings, Paul J. (Nkarta 291802– CEO before OncoMed 200601– CEO before QLT Inc CEO)
	Person 2	Mahmood, Nadir (Nkarta 201901 SVP Corporate Development)
	Region	South San Francisco, CA
	Country	United States (USA)
	Street	6000 Shoreline Court Suite 102
	City	94080 South San Francisco, CA
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Nkarta Inc.. (7/10/20). "Press Release: Nkarta Announces Pricing of Initial Public Offering". South San Francisco, CA.
		Record changed: 2023-07-10

Advertisement

More documents for Nkarta Inc. (Nkarta Therapeutics) (NKTX)

• [1] Nkarta Inc.. (4/28/22). "Press Release: Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares". South San Francisco, CA....
• [2] Nkarta Inc.. (4/25/22). "Press Release: Nkarta Announces Proposed Public Offering of Common Stock". South San Francisco, CA....
• [3] Nkarta Inc.. (4/25/22). "Press Release: Nkarta Announces Pricing of Upsized Public Offering of Common Stock". South San Francisco, CA....
• [4] Nkarta Inc.. (4/25/22). "Press Release: Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs". South San Francisco, CA....
• [5] CRISPR Therapeutics AG. (5/6/21). "Press Release: CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer". Zug, Cambridge, MA & South San Francisco, CA....
• [6] Nkarta Inc.. (7/10/20). "Press Release: Nkarta Announces Pricing of Initial Public Offering". South San Francisco, CA....
• [7] Nkarta Inc.. (12/10/18). "Press Release: Nkarta Therapeutics Announces Appointment of Matthew Plunkett, Ph.D., as Chief Financial Officer". South San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.